“I am excited for this interview. The open ended timing is interesting to me, as it seems to line up with the potential release of mild to moderate data.”

Careful, these type of assumptions got a lot of investors hopes up over the past couple of weeks. I’d say the interview will reinforce what Dr. BP has said in the past and maybe a few nuggets on the paper. Besides that, he isn’t able to discuss any deductions he has made from reviewing the samples from the mild/mod and severe trials because I don’t think the FDA would like that.